Årdal has worked for 20 years on access to medicines through different sectors, including research institutes, governmental development assistance, pharmaceutical industry, pharmacy, national health service and insurance. She has worked in the U.S., U.K. and Norway. She was a member of the World Health Organization expert review panel for the overall programme review of the Global Strategy and Plan of Action on public health, innovation and intellectual property. She led the Norwegian Agency for Development Cooperation’s (Norad) efforts within the UN Commission on Life-Saving Commodities for Women and Children. She was also a member of the Secretariat for WHO’s Consultative Expert Working Group on R&D: Financing and Coordination. She currently works for the Norwegian Institute of Public Health (NIPH) with a focus on the policy aspects of antimicrobial resistance. Årdal was a co-lead for the DRIVE-AB research project which aimed to transform the way policymakers stimulate innovation, the sustainable use, and the equitable availability of novel antibiotics to meet unmet public health needs. She is currently the co-lead of the research and innovation work package for the European Union’s Joint Action on Antimicrobial Resistance. She received a master of business administration from the Rotterdam School of Management and her PhD (alternative business models for discovering and developing new medicines for “neglected” diseases, particularly open source drug discovery) from the University of Oslo.